Friedhelm Blobel, Ph.D.
Friedhelm Blobel, Ph.D., has been our President, Chief Executive Officer and a Director since June 2, 2006. Before joining the Company, Dr. Blobel served most recently as President, Chief Executive Officer and a Director of Gryphon Therapeutics, Inc., a South San Francisco based biopharmaceutical company. Prior to joining Gryphon in July 2000, Dr. Blobel spent more than 20 years as an executive with the Hoechst Group and the Boehringer Mannheim Group, including many responsibilities in the areas of diabetes and in vitro diagnostics. His roles at these companies included Group President of several product divisions, Chief Technology Officer, General Manager of a marketing and sales joint venture between Boehringer and Yamanouchi Pharmaceuticals (now Astellas) in Tokyo, Japan, Senior Vice President of Research & Development Diabetes and Patient Care in Mannheim, Germany as well as in Indianapolis, Indiana. Dr. Blobel earned his doctorate degree (“Dr.rer.nat.”; a Ph.D. equivalent) with a dissertation in Biochemistry and Microbiology from the University of Hohenheim, Germany and holds an advanced degree in Chemistry from the University of Stuttgart, Germany. He serves as a Director of Pelikan Technologies, Inc., a Palo Alto based private Biotech company.
back to top

Hans P. Schmid
Hans P. Schmid is the President and Managing Director of SciClone Pharmaceuticals International, Ltd. and has been with the Company since 2001. Mr. Schmid has 25 years of financial and pharmaceutical experience in the U.S. and international markets. Prior to joining SciClone, Mr. Schmid was Chief Financial Officer from December 1999 to April 2001 for Questcor Pharmaceuticals, Inc. and Senior Vice President, International Business Development from February 1997 to September 1999 for Oread, Inc., a contract pharmaceutical company. From 1985 to 1997 he worked at Syntex Corporation as Vice President of Finance and Administration for Pharmaceutical Operations Asia/Pacific region, at F. Hoffmann-LaRoche as Senior Vice President, Finance and Head of Administrative Services for Roche Bioscience. Previously he held financial and operational positions with Itel Corporation in Germany, Japan, England and the U.S. Mr. Schmid received his BA from the Commercial Trade School, Lucerne, Switzerland, and has studied International Business Management and Finance at San Francisco State University. A Swiss, Hans speaks German, French and conversational Japanese.
back to top

Israel Rios, M.D.
Israel Rios, M.D. has served as Chief Medical Officer since joining SciClone Pharmaceuticals, Inc. in October 2005. Dr. Rios has over 25 years of experience in the biotechnology and pharmaceutical industries. Dr. Rios is responsible for the design and oversight of all clinical trials and the evaluation of new development candidates. From 2003 to 2005 he served as Vice President of Clinical Affairs for Dendreon Corporation and was responsible for all clinical and operational activities related to the development of late-stage immunotherapeutic candidates for androgen independent prostate cancer (AIPC) and advanced breast cancer. From 1993 to 2000, Dr. Rios was at Berlex Laboratories (the U.S. affiliate of Schering AG of Germany) most recently as Vice President of Oncology Development. From 1984 to 1993, Dr. Rios was Director of Anti-Infective Clinical Research at Marion Merell Dow, Inc. where he directed the clincal development and helped manage the New Drug Application (NDA) submissions of several anti-infective products. From 1978 to 1984, Dr. Rios held several escalating positions at Bristol-Myers, most recently as Director of Clinical Research. Dr. Rios earned his M.D. degree at the Central University of Venezuela. He completed his internship and residency in internal medicine at Mount Sinai Hospital in Hartford, Connecticut, and his fellowship in infectious diseases at Hartford Hospital in Hartford, Connecticut.
back to top

Cynthia W. Tuthill, Ph.D.
Cynthia W. Tuthill, Ph.D. has served as Senior Vice President, Scientific Affairs and Chief Scientific Officer of SciClone Pharmaceuticals, Inc. since February 2006. Dr. Tuthill was previously Vice President, Scientific Affairs, since joining SciClone in October 1991. Dr. Tuthill has over 20 years of experience in the biotechnology and pharmaceutical industries. At SciClone, Dr Tuthill is responsible for the design and oversight of all non clinical studies. Prior to joining SciClone, Dr. Tuthill was a senior product development scientist at Becton Dickinson Immunocytometry Systems, responsible for development of manufacturing methods, according to Good Manufacturing Processes, for new reagents for the assessment of viral diseases. From 1984 to 1990, she was a senior scientist at California Biotechnology, Inc. (now Scios, Inc.). At California Biotechnology she was project manager for several large heart disease therapeutic projects, as well as being responsible for analysis and purification of recombinant human proteins. Dr. Tuthill earned her undergraduate degree, summa cum laude, from the University of California, Berkeley, and her Ph.D. in protein biochemistry with highest honors from Harvard University.
back to top

Craig A. Halverson
Craig A. Halverson has served as Vice President, Regulatory Affairs and Quality Assurance since January 2008. With over 20 years of experience in the biotechnology industry, Mr. Halverson is responsible for planning and executing global regulatory strategies, managing SciClone’s regulatory affairs and clinical operations for its Chinese business, and supervising quality assurance. Prior to joining SciClone, Mr. Halverson served as Vice President of Regulatory Affairs at ZymoGenetics from 2004-2007, Vice President of Regulatory Affairs and Quality Assurance at Introgen Therapeutics in 2004, Executive Director of Global Regulatory Affairs and Clinical Quality Assurance for Cancervax Corporation from 2001-2004, and Director of Regulatory Affairs at Gen-Probe Incorporated from 1998-2001. He also served as Global Regulatory Affairs Director for Baxter Healthcare Corporation’s Hyland Division from 1994-1998, worked in a number of Research, Regulatory Affairs, Technology Acquisition and Project Management positions of increasing responsibility for Hybritech, Inc. from 1985-1994 and held a number of academic research positions from 1975-1985. Mr. Halverson received his M.S.in Experimental Pathology from the University Southern California and his B.S. in Chemistry and Biology from California State University at Fullerton.
back to top

Eric J. Hoechstetter
Eric J. Hoechstetter has served as Vice President, Legal Affairs since October 2007. Mr. Hoechstetter has 16 years of legal experience, principally international. Prior to joining SciClone, from 2003 to 2006 he was Senior Corporate Counsel at Chiron Corporation’s UK headquarters and oversaw all legal affairs of the Biopharmaceutical Division’s European activities and the company’s corporate governance activities ex-United States. From 1995 to 2003, he worked in Europe for three communications companies, Wanadoo S.A., Level (3) Communications Ltd., and Global One Communications S.A. He began his legal career at White and Case in New York, where he worked from 1990 to 1994. Mr. Hoechstetter received his J.D. degree from Columbia University School of Law and his B.A. degree in Business Administration from University of Michigan. He is a member of the New York bar. A native English speaker, Mr. Hoechstetter also speaks German, French and basic Spanish.
back to top

Randy J. McBeath
Randy McBeath has served as Vice President, Marketing of SciClone Pharmaceuticals, Inc. since May 2000. Mr. McBeath has twenty years of experience in the biotech, pharmaceutical and chemical industry in international sales and marketing, general management, business development, research and development, and manufacturing. At SciClone, Mr. McBeath is responsible for the worldwide development of promotional and educational materials as well as training programs to support ZADAXIN marketing worldwide. Prior to joining SciClone, Mr. McBeath served as the Director of Marketing for Coulter Pharmaceuticals from 1997 to 1999. From 1989 to 1997, Mr. McBeath was the Global Director of Marketing for Mallinckrodt Medical's Oncology Group, Senior Product Director in their Nuclear Medicine division, and served as a Western Regional Sales Manager for Monsanto Company. Mr. McBeath received his M.B.A. degree with honors from the Olin School of Business at Washington University in St. Louis and his B.S. degree in Biochemistry from the University of Missouri where he was a Curator's Scholar.
back to top